Cargando…

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

The contribution of influenza B to the seasonal influenza burden varies from year-to-year. Although 2 antigenically distinct influenza B virus lineages have co-circulated since 2001, trivalent influenza vaccines (TIVs) contain antigens from only one influenza B virus. B-mismatch or co-circulation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray, Riju, Dos Santos, Gaël, Buck, Philip O., Claeys, Carine, Matias, Gonçalo, Innis, Bruce L., Bekkat-Berkani, Rafik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512791/ https://www.ncbi.nlm.nih.gov/pubmed/28532276 http://dx.doi.org/10.1080/21645515.2017.1313375

Ejemplares similares

Influenza: Can we cope better with the unpredictable?
por: Dos Santos, Gaël, et al.
Publicado: (2015)

Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review
por: Dos Santos, Gael, et al.
Publicado: (2018)

2319. Clinical Predictors of Influenza and Hospitalization of Children with Influenza in an Emergent Care Setting
por: Rao, Suchitra, et al.
Publicado: (2019)

Seasonal influenza vaccination in patients with COPD: a systematic literature review
por: Bekkat-Berkani, Rafik, et al.
Publicado: (2017)

Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
por: Molnar, Daniel, et al.
Publicado: (2022)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

Assessing direct and indirect effects of pediatric influenza vaccination in Germany by individual-based simulations
por: Schmidt-Ott, Ruprecht, et al.
Publicado: (2019)

986. Evaluation of Moderate-to-Severe Influenza Disease in Children 6 Months to 8 Years of Age in Colorado
por: Rao, Suchitra, et al.
Publicado: (2018)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
por: Kieninger, Dorothee, et al.
Publicado: (2013)

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children
por: Claeys, Carine, et al.
Publicado: (2019)

Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US children
por: Hsiao, Amber, et al.
Publicado: (2020)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Vaccines against Meningococcal Diseases
por: Pizza, Mariagrazia, et al.
Publicado: (2020)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis
por: de Lusignan, Simon, et al.
Publicado: (2018)

Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis
por: Dos Santos, Gael, et al.
Publicado: (2019)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
por: Tisa, V., et al.
Publicado: (2016)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season
por: Dos Santos, Gaël, et al.
Publicado: (2019)

Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018
por: Boikos, Constantina, et al.
Publicado: (2020)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
por: Jamotte, Aurélien, et al.
Publicado: (2016)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Changing patterns of invasive meningococcal disease and future immunization strategies
por: Taha, Muhamed-Kheir, et al.
Publicado: (2023)

Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults
por: Claeys, Carine, et al.
Publicado: (2018)

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine
por: Jain, Varsha K, et al.
Publicado: (2014)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine
por: Wan, Zhimin, et al.
Publicado: (2018)

02. Beyond B Antigen Coverage: The Potential of the 4CMenB Vaccine for Cross-protection Against Pathogenic Neisseria Infections
por: Garcia, Yara Ruiz, et al.
Publicado: (2021)

Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2020)

Will a Quadrivalent Vaccine Solve the Problem of Influenza B Mismatches?
por: Choi, Eun Hwa, et al.
Publicado: (2018)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f1ufrt3nhesuahlsfctjrajldt